Content about Leo Pharma

September 7, 2012
McKesson Patient Relationship Solutions a finalist in two separate healthcare marketing award races

McKesson Patient Relationship Solutions has been named a finalist in both the 2012 Medical Marketing and Media Awards and the PM360 Trailblazer Awards, McKesson announced Friday.

SCOTTSDALE, Ariz. — McKesson Patient Relationship Solutions has been named a finalist in both the 2012 Medical Marketing and Media Awards and the PM360 Trailblazer Awards, McKesson announced Friday.

McKesson was named a finalist by MM&M in the "Best Use of Direct Marketing to Consumers" category for its "Lap-Band Behavioral Call" campaign on behalf of Ogilvy Healthworld and Allergan. The MM&M Awards annually recognize creativity and marketing effectiveness in health care.

August 6, 2012
Sandoz launches generic psoriasis treatment

Sandoz has launched a generic version of a topical medication used to treat psoriasis, the company said.

PRINCETON, N.J. — Sandoz has launched a generic version of a topical medication used to treat psoriasis, the company said.

Sandoz, the generics arm of Swiss drug maker Novartis, announced the launch of calcipotriene cream in the 0.005% strength, calling it the first generic version of Leo Pharma's Dovonex.

Dovonex had sales of about $118.8 million during the 12-month period ended in May, according to IMS Health.

January 25, 2012
FDA approves actinic keratosis treatment

The Food and Drug Administration has approved a topical treatment made by Leo Pharma for a skin condition that can lead to cancer, the drug maker said Wednesday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a topical treatment made by Leo Pharma for a skin condition that can lead to cancer, the drug maker said Wednesday.

Leo announced the FDA approval of Picato (ingenol mebutate) gel in the 0.015%/0.05% strength for actinic keratosis, also known as AK, which is a precancerous condition resulting from cumulative sun exposure that has the potential to lead to squamous cell carcinoma.

February 22, 2011
Perrigo files regulatory application for Taclonex generic

Generic drug maker Perrigo has filed for approval of a drug to treat psoriasis with the Food and Drug Administration.

ALLEGAN, Mich. — Generic drug maker Perrigo has filed for approval of a drug to treat psoriasis with the Food and Drug Administration.

Perrigo announced Tuesday that it had filed an application with the FDA for calcipotriene and betamethasone dipropionate in the 0.005%/0.064% strength. The drug is a generic version of Leo Pharma’s Taclonex and is used to treat psoriasis vulgaris in adults.